“Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis

BACKGROUND: SARS-CoV-2 infection demonstrates a wide range of severity, with more severe cases presenting with a cytokine storm with elevated serum interleukin-6; hence, the interleukin-6 receptor antibody tocilizumab was used for the management of severe cases. OBJECTIVE: To explore the effect of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mady, Ahmed F., Abdulrahman, Basheer, Mumtaz, Shahzad A., Al-Odat, Mohammed A., Kuhail, Ahmed, Altoraifi, Rehab, Alshae, Rayan, Alharthy, Abdulrahman M., Aletreby, Waleed Th.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242887/
https://www.ncbi.nlm.nih.gov/pubmed/35839546
http://dx.doi.org/10.1016/j.hrtlng.2022.06.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242887/
https://www.ncbi.nlm.nih.gov/pubmed/35839546
http://dx.doi.org/10.1016/j.hrtlng.2022.06.024

Ejemplares similares